Navigation Links
10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
Date:2/19/2009

bes placed into a large vein in a patient's neck, chest or groin to administer medication or fluids or to collect blood samples.

Each year, an estimated 250,000 cases of central line-associated bloodstream infections occur in hospitals in the United States, leading to at least 30,000 deaths, according to the Centers for Disease Control and Prevention. The average additional hospital cost for each infection is over $36,000, which totals over $9 billion in excess costs annually. Thus results from this project can potentially improve care, save lives, and lead to substantial cost savings for participating hospitals and the health care system.

The comprehensive safety program is designed to help ICU staff ensure patient safety. The program, which has been used successfully in more than 100 ICUs in Michigan, includes tools to help health care professionals identify opportunities to reduce potential health care-associated infections and implement policies to make care safer. Within 3 months of implementation in Michigan, the program helped reduce infection rates to zero in more than 50 percent of participating hospitals.

The new 10-state project aims to reduce the average rate of central line-associated blood stream infections in hospitals by 80 percent, from the national average of five infections per 1,000 catheter days to one infection for every 1,000 catheter days. Researchers from HRET, Johns Hopkins University School of Medicine, and the Keystone Center for Patient Safety & Quality in Michigan will work together to provide participating hospitals with the necessary tools and training to reduce these infections in their ICUs. Participating hospitals will implement a checklist to ensure compliance with safety practices, educate staff on evidence-based practices to reduce bloodstream infections, educate staff on team training, provide feedback on infection rates to hospitals and hospital units, and imp
'/>"/>

SOURCE Agency for Healthcare Research & Quality
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
2. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
3. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
4. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
5. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
6. QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS
7. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
8. ACORNs Oncology-focused Contract Research Organization Exceeds Projections
9. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
10. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
11. Hospital Launches Landmark Emergency Medicine Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... financial results for its third quarter ended September 30, ... September 30, 2011 were $102,238 as compared to $34,446 ... nine months ended September 30, 2011, revenues were $257,609, ...
... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, ... Senior Vice President and Chief Medical Officer. ... experience in the medical field.  He comes most recently ... and Medical Director of Global Businesses since 2005. In ...
Cached Medicine Technology:Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 2Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 3Prometheus Announces New Chief Medical Officer 2
(Date:11/27/2014)... VeloReality Inc. President Gary Bauer announced ... (RLVs) of world-famous velo courses for the company's VRide software ... popular indoor velo trainers. Two dozen additional Real Life Videos ... of November -- in time for the 2014 holiday ... in the VeloReality collection to over sixty. , The new ...
(Date:11/26/2014)... Il (PRWEB) November 27, 2014 ... excited to announce the kick-off of its annual ... encourages people to go to donate to those ... partner with local organizations to distribute the donations ... 20th, participating AlignLife locations will be accepting donations ...
(Date:11/26/2014)... Recently, Locks-Magnetic.com, a Chinese outstanding Maglocks ... magnetic locks on the Internet. It also provides a ... , As a leading company in the electronic ... customers to buy high quality locks. It can meet ... locks that are not only useful but also affordable. ...
(Date:11/26/2014)... Pharmaceutical and biotech companies require precise control ... and research activities, a task in which HVAC ... key role. Changes in temperature can promote the ... affect the quality of drugs and also support ... to address these problems and keeps the product ...
(Date:11/26/2014)... Alex Kramer HealthDay Reporter ... with rheumatoid arthritis may be more likely to achieve remission ... research. The study found that those who were heaviest ... underweight also lowered the odds of remission. "Medication for ... said Dr. Susan Goodman, the study,s lead author and a ...
Breaking Medicine News(10 mins):Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3Health News:Fresh Products Launched by Famous Company Lock-Magnetic.com 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 5Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3
... People with bipolar,disorder and depression can find hope ... Health Care Decision Support system, available,through the Web site ... resources to support health decisions including:, -- ... depression;, -- links to online and ...
... Federal ... Regulation, ... the availability of DRA Tool(TM), a new feature of its,Sentinel RCM(TM) ... editing module that comprehensively supports the,additional reporting requirements of Section 6002 ...
... will showcase an,experimental model of a walking assist device ... with weakened leg muscles, at the,International Trade Fair on ... Disabled (BARRIER FREE 2008) which will be held at ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU095A ), Designed for people ...
... but nursing home study says risk greatest week after meds ... home patients who take antipsychotic drugs are 60 percent more ... who don,t take the drugs, a new study shows. , ... start taking the medications and gradually decreases, say Dutch researchers. ...
... surgeries has declined, so has death rate, study ... that perform fewer cardiac bypass operations don,t have more ... greater number of bypasses, a new study says. , ... hospitals that do more cardiac bypass operations have better ...
... for,Innovative Technology (CIT) today announced that CIT GAP ... Regeneration, LLC (STR), a medical,device company based in ... regeneration. CIT will invest $100,000., Joseph W. ... and counsel will help us begin developing the ...
Cached Medicine News:Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 2Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 3Health News:Sentry Data Systems Announces Deficit Reduction Act Compliance Tool 2Health News:Honda to Showcase Experimental Walking Assist Device 2Health News:Antipsychotic Drugs Linked to Pneumonia in Elderly 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 3Health News:CIT GAP Funds Invests in STR, LLC 2
... All of DOA Panel Test ... step in vitro test. It ... drug substances in human urine ... evaluated in the point of ...
... This device is a qualitative ... to inspect the,overdose usage of ... a metabolite of,cocaine, in human ... of 300 ng/mL. It is ...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... AcT diff2 delivers performance, ... office labs and smaller laboratories. ... that offers a small sample ... closed analysis modes, a wide ...
Medicine Products: